share_log

信達生物:自願公告 - 國家藥品監督管理局批准耐立克(奧雷巴替尼片)用於治療對一代和二代TKI耐藥和/或不耐受的CML-CP患者

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES OLVEREMBATINIB FOR THE TREATMENT OF CML-CP PATIENTS WHO ARE RESISTANT AND/OR INTOLERANT TO 1st AND 2nd GENERATION TKI TREATMENT

香港交易所 ·  Nov 17, 2023 09:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more